Skip to content
Medical Health Aged Care

Listing on the Tokyo Stock Exchange Prime Market

Rigaku Holdings Corporation < 1 mins read
TOKYO--BUSINESS WIRE--

Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has completed its listing on the Tokyo Stock Exchange Prime Market as of today.

Note: This document is a press release intended for public announcement regarding Rigaku's listing on the Tokyo Stock Exchange Prime Market. It has not been prepared for the purpose of soliciting investments or any similar acts, whether within or outside Japan.

This press release does not constitute an offer or sale of securities in the United States. The shares of common stock of Rigaku may not be offered or sold in the United States absent registration or an exemption from requirement. If any public offering of the shares of common stock of Rigaku is made in the United States, it will be by means of a prospectus that may be obtained from Rigaku or the selling shareholders and that will contain detailed information about Rigaku and its management, as well as financial statements. No public offering of the shares of common stock of Rigaku will take place in the United States.


Contact details:

Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
+81 90 6331 9843
[email protected]

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.